Skip to content

Iain S. Mcgregor

25 papers in the library · 470 citations · publishing 1993-2026

Papers

Sort Most recent Most cited

Quantitative multi-tissue profiling of tryptamines, phenethylamines, and β-carbolines across 53 species of Australian Acacia

Biochemical Systematics and Ecology October 7, 2026 Monique Anne Jacqueline McDonald, Matthew Nolan, Rebecca Gordon et al.

The genus Acacia , comprising approximately 1000 native Australian species, represents a major contributor to the biodiversity of the continent. Some species of Acacia are known to contain bioactive alkaloids, including the popular psychedelic N,N-dimethyltryptamine (DMT). However, systematic phytochemical characterisation across different species of Acacia and tissue types remains limited....

Does acute stress induced via cold water immersion increase blood THC concentrations in regular cannabis users?

Psychopharmacology December 2025 Danielle McCartney, Jordan Levoux, Rebecca Gordon et al.

RATIONALE: Δ9-tetrahydrocannabinol (THC), the principal intoxicant in cannabis, is a highly lipophilic substance that is readily stored in fat. Preclinical research suggests that fat-stored THC can be released into circulation under lipolytic conditions, such as stress. However, compelling evidence of this phenomenon is lacking in humans. OBJECTIVES: Here, we investigated the effects of acute...

DOI: 10.1007/s00213-025-06833-8 (opens in new tab) Full text (opens in new tab) Biomarkers Cannabinoid Cognition Drug testing +5

Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey.

Journal of Eating Disorders July 24, 2025 Sarah-Catherine Rodan, Noah Meez, Sophie Lloyd-Hurwitz et al. 2 citations

There are few effective treatments for eating disorders (EDs), and new interventions are urgently needed. The MEDication and other drugs For Eating Disorders ("MED-FED") survey investigated the lived experience of adults with EDs regarding their prescription and non-prescription drugs use. Psychedelic drugs were highly rated in this survey for their impact on ED symptoms and general mental...

Prescription and Nonprescription Drug Use Among People With Eating Disorders.

JAMA Network Open July 1, 2025 Sarah-Catherine Rodan, Sarah Maguire, Noah Meez et al. 5 citations

There are few effective pharmacotherapies for treating eating disorders (EDs). High rates of substance use among individuals with EDs suggest potential self-medication of symptoms. To explore the experiences of individuals with EDs regarding use of prescribed and nonprescribed drugs. This survey study assessed responses to the Medications and Other Drugs for Eating Disorders (MED-FED) survey,...

Tetrahydrocannabinol and Cannabidiol in Tourette Syndrome.

NEJM evidence September 2023 Philip E Mosley, Lachlan Webb, Anastasia Suraev et al.

BACKGROUND: Tourette syndrome is characterized by chronic motor and vocal tics. There is preliminary evidence of benefit from cannabis products containing Δ9-tetrahydrocannabinol (THC) and that coadministration of cannabidiol (CBD) improves the side-effect profile and safety. METHODS: In this double-blind, crossover trial, participants with severe Tourette syndrome were randomly assigned to a...

Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis

Psychopharmacology October 13, 2022 Nadia R. P. W. Hutten, Thomas R. Arkell, Frederick Vinckenbosch et al. 36 citations

RATIONALE: Delta-9-tetrahydrocannabinol (THC), an active component of cannabis, can cause anxiety in some users during intoxication. Cannabidiol (CBD), another constituent of cannabis, has anxiolytic properties suggesting that cannabis products containing CBD in addition to THC may produce less anxiety than THC-only products. Findings to date around this issue have been inconclusive and could...

Sex differences in acute cannabis effects revisited: Results from two randomized, controlled trials

Addiction Biology December 22, 2021 Thomas R. Arkell, Richard C. Kevin, Frederick Vinckenbosch et al. 45 citations

Some evidence suggests that males and females may differ in their responses to acute cannabis effects, including subjective drug effects and behavioural effects, and cannabinoid pharmacokinetics. This is significant given current changes to cannabis-related policies and, in consequence, increased cannabis accessibility. The present study combines data from two randomized controlled trials to...

DOI: 10.1111/adb.13125 (opens in new tab) Cannabidiol Randomized controlled trial Effects of cannabis Cannabis dependence +1

Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa

OBM Neurobiology June 24, 2021 Sarah-Catherine Rodan, Phillip Aouad, Iain S. Mcgregor et al. 10 citations

Anorexia Nervosa (AN) is a major health problem with one of the highest mortalities and treatment costs of any psychiatric condition. Cognitive behavioural therapy (CBT) is currently the most widely used treatment for AN in adults but provides remission rates ≤ 50%. Treatment drop-out is exceedingly high and those that persevere with treatment often relapse, causing increased risk of morbidity...

Dark Classics in Chemical Neuroscience: Δ9-Tetrahydrocannabinol.

ACS Chemical Neuroscience May 15, 2019 Samuel D Banister, Jonathon C Arnold, Mark Connor et al.

Cannabis ( Cannabis sativa) is the most widely used illicit drug in the world, with an estimated 192 million users globally. The main psychoactive component of cannabis is (-)- trans-Δ9-tetrahydrocannabinol (Δ9-THC), a compound with a diverse range of pharmacological actions. The unique and distinctive intoxication caused by Δ9-THC primarily reflects partial agonist action at central...

Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition

Psychopharmacology May 1, 2019 Thomas R. Arkell, Nicholas Lintzeris, Richard C. Kevin et al. 177 citations

BACKGROUND: The main psychoactive component of cannabis, delta-9-tetrahydrocannabinol (THC), can impair driving performance. Cannabidiol (CBD), a non-intoxicating cannabis component, is thought to mitigate certain adverse effects of THC. It is possible then that cannabis containing equivalent CBD and THC will differentially affect driving and cognition relative to THC-dominant cannabis. AIMS:...

Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA.

Journal of Psychopharmacology June 2017 Richard C. Kevin, Katie E Wood, Jordyn Stuart et al.

Synthetic cannabinoids (SCs) have rapidly proliferated as recreational drugs, and may present a substantial health risk to vulnerable populations. However, information on possible effects of long-term use is sparse. This study compared acute and residual effects of the popular indazole carboxamide SC compounds AB-PINACA and AB-FUBINACA in adolescent rats with ∆9-tetrahydrocannabinol (THC) and...

DOI: 10.1177/0269881116684336 (opens in new tab) Full text (opens in new tab) Ab-fubinaca Ab-pinaca Cannabinoid Adolescent +2

MDMA ('Ecstasy'), oxytocin and vasopressin modulate social preference in rats: A role for handling and oxytocin receptors.

Pharmacology, Biochemistry, and Behavior 2016 Linnet Ramos, Callum Hicks, Alex Caminer et al.

In laboratory rats, peripheral administration of the neuropeptides oxytocin (OT) and vasopressin (AVP) induces similar prosocial effects (i.e. increased adjacent lying) to the party drug 3,4-methylenedioxymethamphetamine (MDMA), which are sensitive to vasopressin V1A receptor (V1AR) antagonism. Here, we employed a social preference paradigm to further compare the prosocial effects of OT, AVP...

Oxytocin and MDMA ('Ecstasy') enhance social reward in rats.

Psychopharmacology July 2015 Linnet Ramos, Callum Hicks, Alex Caminer et al.

Oxytocin (OT), vasopressin (AVP) and 3,4 methylenedioxymethamphetamine (MDMA, 'Ecstasy') all increase social interaction in rats, perhaps by enhancing the rewarding value of social encounters. Here, we used the conditioned place preference (CPP) paradigm to assess the intrinsic rewarding effects of OT, AVP and MDMA, and whether these effects are enhanced by the presence of a conspecific, or a...

Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats.

Psychopharmacology November 2011 Charlotte Klein, Emily Karanges, Adena Spiro et al.

The interactions between Δ(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD) during chronic treatment, and at equivalent doses, are not well characterised in animal models. The aim of this study is to examine whether the behavioural effects of THC, and blood and brain THC levels are affected by pre-treatment with equivalent CBD doses. Adolescent rats were treated with ascending daily THC...

Mephedrone (4‐methylmethcathinone, ‘meow’): acute behavioural effects and distribution of Fos expression in adolescent rats

Addiction Biology October 13, 2011 Craig P. Motbey, Glenn E. Hunt, Michael Bowen et al. 92 citations

Mephedrone (4-methylmethcathinone) is a novel recreational drug that has rapidly increased in popularity in recent years. Users report mephedrone as having the stimulant-like qualities of methamphetamine and cocaine, combined with the prosocial, entactogenic effects of 3,4-methylenedioxymethamphetamine (MDMA). Anecdotal and case study reports indicate that mephedrone may have the potential to...

The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids.

The International Journal of Neuropsychopharmacology June 2011 Aurelie A Boucher, Glenn E. Hunt, Jacques Micheau et al.

Cannabis increases the risk of schizophrenia in genetically vulnerable individuals. In this study we aim to show that the schizophrenia susceptibility gene neuregulin 1 (Nrg1) modulates the development of tolerance to cannabinoids in mice. Nrg1 heterozygous (HET) and wild-type (WT) mice were treated daily for 15 d with the synthetic analogue of Δ9-tetrahydrocannabinol, CP55,940 (0.4 mg/kg). We...

A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.

The International Journal of Neuropsychopharmacology August 2010 Leonora E Long, Rose Chesworth, Xu-Feng Huang et al.

Cannabis contains over 70 unique compounds and its abuse is linked to an increased risk of developing schizophrenia. The behavioural profiles of the psychotropic cannabis constituent Delta9-tetrahydrocannabinol (Delta9-THC) and the non-psychotomimetic constituent cannabidiol (CBD) were investigated with a battery of behavioural tests relevant to anxiety and positive, negative and cognitive...

Reintoxication: the release of fat-stored delta(9)-tetrahydrocannabinol (THC) into blood is enhanced by food deprivation or ACTH exposure.

British Journal of Pharmacology November 2009 Nathan Gunasekaran, L E Long, B L Dawson et al.

Delta(9)-tetrahydrocannabinol (THC), the main psychoactive constituent of cannabis, accumulates in adipose tissue where it is stored for long periods of time. Here we investigated whether conditions that promote lipolysis can liberate THC from adipocytes to yield increased blood levels of THC. In vitro studies involved freshly isolated rat adipocytes that were incubated with THC before exposure...

Neural correlates of MDMA (“Ecstasy”)-induced social interaction in rats

Social Neuroscience June 21, 2008 Murray R. Thompson, Glenn E. Hunt, Iain S. Mcgregor 48 citations

The popular drug 3,4 methylenedioxymethamphetamine (MDMA, "Ecstasy", "the Love Drug") produces feelings of love and closeness in humans and induces analogous prosocial and antiaggressive effects in laboratory animals. Here we examined the specific brain regions that may be involved in these prosocial effects. Male Wistar rats were pretreated with a moderate dose of MDMA (5 mg/kg) or vehicle and...

From ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long-term adverse consequences of drug use?

British Journal of Pharmacology May 2008 Iain S. Mcgregor, P D Callaghan, G E Hunt

Addictive drugs can profoundly affect social behaviour both acutely and in the long-term. Effects range from the artificial sociability imbued by various intoxicating agents to the depressed and socially withdrawn state frequently observed in chronic drug users. Understanding such effects is of great potential significance in addiction neurobiology. In this review we focus on the 'social...

Repeated weekly exposure to MDMA, methamphetamine or their combination: long-term behavioural and neurochemical effects in rats.

Drug and Alcohol Dependence January 12, 2007 Kelly J. Clemens, Jennifer L. Cornish, Glenn E. Hunt et al.

In recent work we have documented lasting adverse neurochemical and behavioural effects in rats given short-term 'binge' dosing with methylenedioxymethamphetamine (MDMA, Ecstasy), methamphetamine (METH) or their combination. Here we investigated whether similar effects persist in rats given 16 weekly injections followed by a 10 week period of abstinence. Female rats received MDMA (8 mg/kg,...

MDMA, methamphetamine and their combination: possible lessons for party drug users from recent preclinical research

Drug and Alcohol Review 2007 Kelly J. Clemens, Iain S. Mcgregor, Glenn E. Hunt et al. 55 citations

Abstract The substituted amphetamines 3,4‐methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) and methamphetamine (METH, ‘ice’, ‘speed’) are increasingly popular drugs amongst party‐drug users. Studies with humans have investigated the acute and possible long‐term adverse effects of these drugs, yet outcomes of such studies are often ambiguous due to a variety of confounding factors. Studies...

Co-administration of THC and MDMA ('ecstasy') synergistically disrupts memory in rats.

Neuropsychopharmacology August 2005 June M Young, Iain S. Mcgregor, Paul E Mallet

3,4-Methylenedioxymethamphetamine (MDMA, 'Ecstasy') and cannabis are two of the most commonly used illicit drugs in the western world, and are often used in combination. Very little research has examined their effect on cognitive function or behavior when combined, The present study used a double Y-maze task to examine the acute effect of MDMA and delta9-tetrahydrocannabinol (THC, the principal...

Contrasting effects of dopaminergic blockade on MDMA and d-amphetamine conditioned taste aversions.

Pharmacology, Biochemistry, and Behavior February 1994 H Q Lin, Iain S. Mcgregor, D M Atrens et al.

A series of experiments examined the role of dopamine in the conditioned taste aversion (CTA) produced by 3,4-methylenedioxymethamphetamine (MDMA) and d-amphetamine in rats. The CTA induced by MDMA (1.0 mg/kg) was unaffected by the D1 dopamine receptor antagonist SCH23390 (0.3 or 0.6 mg/kg), the D2 receptor antagonist raclopride (0.3 or 0.6 mg/kg), SCH23390 and raclopride combined (both 0.3 or...

Comparison of conditioned taste aversions produced by MDMA and d-amphetamine.

Pharmacology, Biochemistry, and Behavior September 1993 H Q Lin, D M Atrens, M J Christie et al.

Many drugs of abuse such as d-amphetamine support the development of taste aversion in a conditioned taste aversion paradigm. However, it has yet to be established whether methylenedioxymethamphetamine (MDMA), an amphetamine-like stimulant, has this property. A direct comparison was made between MDMA and d-amphetamine over a dose range of 0.125-2.0 mg/kg (SC). Two pairings of either drug with...